These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 16856613

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Treatment and vaccination for hepatitis C: present and future.
    Jawaid A, Khuwaja AK.
    J Ayub Med Coll Abbottabad; 2008; 20(1):129-33. PubMed ID: 19024206
    [Abstract] [Full Text] [Related]

  • 23. Future therapy of hepatitis C.
    McHutchison JG, Patel K.
    Hepatology; 2002 Nov; 36(5 Suppl 1):S245-52. PubMed ID: 12407600
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [Abstract] [Full Text] [Related]

  • 25. New drugs for hepatitis C virus.
    Pockros PJ.
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):145-54. PubMed ID: 19072442
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Treating hepatitis C: the state of the art.
    Gish RG.
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S1-9. PubMed ID: 15081099
    [Abstract] [Full Text] [Related]

  • 28. Serine protease inhibitors as anti-hepatitis C virus agents.
    Reiser M, Timm J.
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
    [Abstract] [Full Text] [Related]

  • 29. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J, del Pilar Moreno M, Moratorio G.
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Novel hepatitis C drugs in current trials.
    Kronenberger B, Welsch C, Forestier N, Zeuzem S.
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [Abstract] [Full Text] [Related]

  • 32. Current and future management of chronic hepatitis C infection.
    Cross TJ, Antoniades CG, Harrison PM.
    Postgrad Med J; 2008 Apr; 84(990):172-6. PubMed ID: 18424572
    [Abstract] [Full Text] [Related]

  • 33. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
    Herion D, Hoofnagle JH.
    Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
    [No Abstract] [Full Text] [Related]

  • 34. [Fluctuation of hepatitis C virus quasispecies with interferon treatment and interferon-resistant variants in hepatitis C virus 1b].
    Sakuma I, Enomoto N, Asahina Y, Kurosaki M, Sato C.
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):930-5. PubMed ID: 7563904
    [No Abstract] [Full Text] [Related]

  • 35. Hepatitis C therapy before and after liver transplantation.
    Terrault NA.
    Liver Transpl; 2008 Oct; 14 Suppl 2():S58-66. PubMed ID: 18825697
    [Abstract] [Full Text] [Related]

  • 36. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
    Shedlofsky SI.
    Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
    [No Abstract] [Full Text] [Related]

  • 37. Treating hepatitis C virus in HIV patients: are side effects a real obstacle?
    Gatti F, Nasta P, Matti A, Manno D, Mendeni M, Puoti M, Carosi G.
    AIDS Rev; 2007 May; 9(1):16-24. PubMed ID: 17474310
    [Abstract] [Full Text] [Related]

  • 38. Approaches for the development of antiviral compounds: the case of hepatitis C virus.
    Schinazi RF, Coats SJ, Bassit LC, Lennerstrand J, Nettles JH, Hurwitz SJ.
    Handb Exp Pharmacol; 2009 May; (189):25-51. PubMed ID: 19048196
    [Abstract] [Full Text] [Related]

  • 39. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders.
    Freedman K, Nathanson J.
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):363-76. PubMed ID: 19344248
    [Abstract] [Full Text] [Related]

  • 40. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
    Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS.
    Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.